The alfapump® system is not currently approved in the United States or Canada. In the United States and Canada, the alfapump® system is currently under clinical investigation (POSEIDON Study) and is being studied in adult patients with refractory or recurrent ascites due to cirrhosis. For more information regarding the POSEIDON clinical study see www.poseidonstudy.com.
The DSR® therapy is still in development and it should be noted that any statements regarding safety and efficacy arise from ongoing pre-clinical and clinical investigations which have yet to be completed.
The DSR® therapy is not currently approved for clinical research in the United States or Canada. There is no link between the DSR® therapy and ongoing investigations with the alfapump® system in Europe.
ISIN: XXXXXXXXXXXXX-XXXX Updated at 11:05:33
Status as of 15 February 2021
Last update: 23 February 2021
This graph represents Sequana Medical’s major shareholders, based on transparency notifications received by the Company, to date.
The Belgian Transparency Act refers to article 14 of the Belgian Act of 2 May 2007 on disclosure of major shareholdings in issuers shares of which are admitted to trading on a regulated market and laying down miscellaneous provision.
Pursuant to this Belgian Transparency Act and the articles of association of the Company, a notification to the Company and the Belgian Financial Services and Markets Authority (FSMA) is required by all natural and legal persons in each case where the percentage of voting rights attached to the securities held by such persons in the Company reaches, exceeds or falls below the threshold of 3%, 5%, 10%, and every subsequent multiple of 5%, of the total number of voting rights in the Company.
For more information and the appropriate transparency forms, please contact Sequana Medical Investor Relations (email@example.com) or the FSMA.
|Shareholder||Date of notification||Transparency notification||Press release|
|Venture Incubator AG / VI Partners AG||19-Feb-2021||Download pdf||23-Feb-2021|
|LSP Health Economics Fund Management B.V.||19-Feb-2021||Download pdf||23-Feb-2021|
|NeoMed IV Extension L.P. / NeoMed Innovation V L.P.||19-Feb-2021||Download pdf||23-Feb-2021|
|Federale Participatie- en Investeringsmaatschappij NV / Belfius Insurance SA||18-Feb-2020||Download pdf||21-Feb-2020|
|Capricorn Heath-tech Fund NV / Quest for Growth NV||14-Feb-2020||Download pdf||21-Feb-2020|
|GRAC Société Simple||30-Jan-2020||Download pdf||03-Feb-2020|
|NeoMed IV Extension L.P. / NeoMed Innovation V L.P.||30-Jan-2020||Download pdf||03-Feb-2020|
|Newton Biocapital I Pricav Privée SA||21-Feb-2019||Download pdf||25-Feb-2019|
|Venture Incubator AG / VI Partners AG||21-Feb-2019||Download pdf||25-Feb-2019|
|NeoMed IV Extension L.P. / NeoMed Innovation V L.P.||20-Feb-2019||Download pdf||25-Feb-2019|
|LSP Health Economics Fund Management B.V.||19-Feb-2019||Download pdf||25-Feb-2019|
|Federale Participatie- en Investeringsmaatschappij N.V.||18-Feb-2019||Download pdf||25-Feb-2019|
|Participatiemaatschappij Vlaanderen NV||18-Feb-2019||Download pdf||25-Feb-2019|
|Capricorn Health-tech Fund NV / Quest for Growth NV||18-Feb-2019||Download pdf||25-Feb-2019|
May 28, 2020
May 23, 2019
April 25, 2019
February 15, 2021
Report of the Statutory Auditor – full version in Dutch only
January 27, 2020
Report of the Statutory Auditor on the proposal of a capital increase (within the framework of the authorized capital) with cancellation of the preferential subscription right – full version in Dutch only
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.